Indian Council of Medical Research COVID-19 Vaccine
Technical Data
| Date of Issue | January 16, 2022 |
|---|---|
| Denomination | Rs. 5 |
| Quantity | 301920 |
| Perforation | comb 14 |
| Printer | Security Printing Press, Hyderabad |
| Watermark | No Watermark |
| Colors | Multicolor |
| Catalog Codes |
Michel IN 3758 Yvert et Tellier IN 3437 Stanley Gibbons IN 3799 |
| Themes | Diseases | Medical Science | |
COVID-19 was declare a pandemic by the World Health Organization (WHO) in March 2020. Since then, the disease has caused significant morbidity and mortality across the World. Development of safe and effective vaccine was identified as the most promising tool to help mount a protective immune response to reduce disease’s severity and curtail transmission. Accordingly, intense global efforts were mounted to develop COVID-19 vaccines.
The story of development of India’s home-grown vaccine, COVAXIN started in April 2020 following successful isolation of the first SARS-CoV-2 virus strain at Indian Council of Medical Research (ICMR)- National Institute of Virology (NIV), Pune, Department of Health Research, Ministry of Health & Family Welfare, Government of India. From here ICMR and Bharat Biotech International Ltd (BBIL), an indigenous Hyderabad based company, embarked upon one of the most successful public private partnership to develop an effective COVID-19 vaccine.
On 3rd November 2021, COVAXIN had been included as the eight vaccine globally to receive the WHO Emergency Use Listing (EUI), after fulfilling the intense review and scrutiny of scientific data and manufacturing processes. Today, as the country is celebrating 75 years of independence, India stands tall in the global community where more than 1.1 billion citizens have been vaccinated for COVID-19.
Department of Posts is pleased to issue a Commemorative Postage Stamp on COVAXIN which is a heart-felt tribute to the healthcare workers, Indian Academia and Industry.